2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. IMPDH

IMPDH

Inosine-5’-monophosphate dehydrogenase

IMPDH is a purine biosynthetic enzyme that catalyzes the conversion of inosine 5'-monophosphate (IMP) to xanthosine 5'-monophosphate (XMP). This is the rate-limiting step in the de novo biosynthesis of guanine nucleotides (GMP), and the reaction requires the coenzyme nicotinamide adenine dinucleotide (NAD+). There are mainly two subtypes of IMPDH, IMPDH1 and IMPDH2. IMPDH is a regulator of the intracellular guanine nucleotide pool, and is therefore important for DNA and RNA synthesis, signal transduction, energy transfer, glycoprotein synthesis, as well as other process that are involved in cellular proliferation. In addition, IMPDH can regulate the activation and proliferation of lymphocytes and affect the immune response. The abnormal expression of IMPDH is closely related to cancer and autoimmune diseases[1][2].

IMPDH Related Products (6):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-13986A
    (R)-Merimepodib
    		Control
    (R)-Merimepodib is the isomer of Merimepodib (HY-13986), and can be used as an experimental control. Merimepodib (VX-497) is a noncompetitive and oral inhibitor of inosine monophosphate dehydrogenase (IMPDH) with broad spectrum antiviral activities.
    (R)-Merimepodib
  • HY-110217
    BMS-566419
    		Inhibitor 99.68%
    BMS-566419 is an acridone-based inhibitors of inosine 5'-monophosphate dehydrogenase (IMPDH). Inosine monophosphate dehydrogenase (IMPDH) is a key enzyme in the de novo synthesis of guanosine nucleotides. BMS-566419 has clinical utility for the research of transplant rejection.
    BMS-566419
  • HY-W700392
    IMPDH-IN-2
    		Inhibitor 98.95%
    IMPDH-IN-2 (compound 2) is an inhibitor of inosine monophosphate dehydrogenase (IMPDH) with IC50IMPDH I and IMPDH II >Values are 0.15 and 0.17 μM, respectively. IMPDH-IN-2 has antitumor activity.
    IMPDH-IN-2
  • HY-174221
    IMPDH II/HDAC1-IN-1
    		Inhibitor
    IMPDH II/HDAC1-IN-1 (Compound C12) is an orally active dual-target inhibitor of IMPDH II and IMPDH II (IC50 values are 84.69 nM and 81.75 nM, respectively). IMPDH II/HDAC1-IN-1 has significant anti-tumor activity and has an anti-proliferative effect on K-562 cells (IC50 = 305.31 nM). IMPDH II/HDAC1-IN-1 exerts a synergistic anti-tumor effect by simultaneously targeting IMPDH II and HDAC1, inhibiting tumor cell proliferation and inducing apoptosis. IMPDH II/HDAC1-IN-1 can be used in the study of cancers such as chronic myeloid leukemia (CML).
    IMPDH II/HDAC1-IN-1
  • HY-117124
    BMS-337197
    		Inhibitor
    BMS-337197 is a IMPDH inhibitor.
    BMS-337197
  • HY-128214
    IMPDH-IN-3
    		Inhibitor
    IMPDH-IN-3 (Compound C67) is an inhibitor of C. parvum IMPDH (CpIMPDH) with an IC50 of 35 nM. IMPDH-IN-3 can be used in the research of anti-Cryptosporidium drugs.
    IMPDH-IN-3